Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Innoviva, Inc. INVA
$12.61
+$0.18 (1.45%)
На 18:00, 12 мая 2023
+3.09%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
807341730.00000000
-
week52high
16.67
-
week52low
10.64
-
Revenue
331339000
-
P/E TTM
3
-
Beta
0.55674700
-
EPS
2.32000000
-
Last Dividend
1.25000000
-
Next Earnings Date
25 июл 2023 г. в 10:59
Описание компании
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Underweight | Underweight | 08 авг 2022 г. |
| Goldman Sachs | Neutral | 20 июл 2022 г. | |
| Morgan Stanley | Underweight | Underweight | 15 июл 2022 г. |
| Morgan Stanley | Underweight | Underweight | 12 апр 2022 г. |
| Morgan Stanley | Underweight | Underweight | 23 февр 2022 г. |
| Morgan Stanley | Underweight | Underweight | 13 окт 2022 г. |
| Morgan Stanley | Underweight | Underweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Zhen Marianne | D | 38653 | 828 | 18 ноя 2022 г. |
| Zhen Marianne | A | 39481 | 433 | 15 ноя 2022 г. |
| Zhen Marianne | D | 39048 | 830 | 19 авг 2022 г. |
| Zhen Marianne | D | 39878 | 828 | 20 мая 2022 г. |
| Zhen Marianne | A | 40706 | 1834 | 13 мая 2022 г. |
| Raifeld Pavel | A | 500000 | 150000 | 02 мая 2022 г. |
| Birx Deborah | A | 10000 | 10000 | 25 апр 2022 г. |
| Birx Deborah | A | 42489 | 12647 | 25 апр 2022 г. |
| Bickerstaff George | A | 10000 | 10000 | 25 апр 2022 г. |
| Bickerstaff George | A | 137207 | 12647 | 25 апр 2022 г. |
Новостная лента
Is Innoviva (INVA) Stock Undervalued Right Now?
Zacks Investment Research
17 апр 2023 г. в 11:28
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Four Undervalued Healthcare Stocks for 2023
MarketBeat
06 янв 2023 г. в 11:21
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
5 Value Stocks With Attractive EV-to-EBITDA Ratios to Snap Up
Zacks Investment Research
17 ноя 2022 г. в 08:17
We have screened value stocks PBF, INVA, GLP, HCCI and STRL based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.
Are Investors Undervaluing Innoviva (INVA) Right Now?
Zacks Investment Research
11 ноя 2022 г. в 11:17
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates
Zacks Investment Research
09 ноя 2022 г. в 20:19
Innoviva (INVA) delivered earnings and revenue surprises of -78.18% and 81.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?